Literature DB >> 19555306

Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium.

Yong-Mei Yin1, Fu-De Cui, Jung Sun Kim, Min-Koo Choi, Byung Chul Choi, Suk-Jae Chung, Chang-Koo Shim, Dae-Duk Kim.   

Abstract

A redispersible dry emulsion (DE) formulation of atorvastatin calcium (AC) was developed to enhance the in vitro dissolution of AC, thereby increasing its gastrointestinal absorption. The spray-drying technology was used where Plurol Oleique CC 497 was chosen as the oil phase. Effects of carriers, surfactants, and homogenizers on the characteristics of DE containing AC were systematically investigated. The final formulation consisted of dextrin and Poloxamer 188 as carrier and surfactant, respectively, and was homogenized by a high pressure homogenizer before spray drying. The in vitro release of AC from the optimized DE was significantly higher than that of pure AC powder (76% vs. 30% at 24 hr). The in vitro intestinal absorption of AC from the DE formulation was 0.77 microg/cm(2) at 2 hr, which was a 2.33-fold increase compared to the pure unformulated AC powder. These results suggest that the oral dry emulsion formulation could improve the intestinal absorption of AC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555306     DOI: 10.1080/10717540802481380

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  4 in total

1.  Dissolution enhancement of atorvastatin calcium by co-grinding technique.

Authors:  Priyanka Prabhu; Vandana Patravale
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

2.  Enhancement of dissolution of atorvastatin through preparation of polymeric solid dispersions using supercritical fluid technology.

Authors:  Bashar Altaani; Rana Obaidat; Walaa Malkawi
Journal:  Res Pharm Sci       Date:  2020-05-11

3.  Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide.

Authors:  Emilie K Langeskov; Kim Kristensen
Journal:  Pharmacol Res Perspect       Date:  2022-08

Review 4.  Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making.

Authors:  Javier Reig-López; Alfredo García-Arieta; Víctor Mangas-Sanjuán; Matilde Merino-Sanjuán
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.